Your browser doesn't support javascript.
loading
Therapeutic Neuroprotection by an Engineered Neurotrophin that Selectively Activates Tropomyosin Receptor Kinase (Trk) Family Neurotrophin Receptors but Not the p75 Neurotrophin Receptor.
Brahimi, Fouad; Galan, Alba; Siegel, Sairey; Szobota, Stephanie; Sarunic, Marinko V; Foster, Alan C; Saragovi, H Uri.
Afiliação
  • Brahimi F; Lady Davis Institute-Jewish General Hospital (F.B., A.G., H.U.S.), Pharmacology and Therapeutics (H.U.S.), and Ophthalmology and Vision Science (H.U.S.), McGill University, Montreal, Quebec, Canada; Otonomy, Inc., San Diego, California (S.Si., S.Sz., A.C.F.); and School of Engineering Science, Simon
  • Galan A; Lady Davis Institute-Jewish General Hospital (F.B., A.G., H.U.S.), Pharmacology and Therapeutics (H.U.S.), and Ophthalmology and Vision Science (H.U.S.), McGill University, Montreal, Quebec, Canada; Otonomy, Inc., San Diego, California (S.Si., S.Sz., A.C.F.); and School of Engineering Science, Simon
  • Siegel S; Lady Davis Institute-Jewish General Hospital (F.B., A.G., H.U.S.), Pharmacology and Therapeutics (H.U.S.), and Ophthalmology and Vision Science (H.U.S.), McGill University, Montreal, Quebec, Canada; Otonomy, Inc., San Diego, California (S.Si., S.Sz., A.C.F.); and School of Engineering Science, Simon
  • Szobota S; Lady Davis Institute-Jewish General Hospital (F.B., A.G., H.U.S.), Pharmacology and Therapeutics (H.U.S.), and Ophthalmology and Vision Science (H.U.S.), McGill University, Montreal, Quebec, Canada; Otonomy, Inc., San Diego, California (S.Si., S.Sz., A.C.F.); and School of Engineering Science, Simon
  • Sarunic MV; Lady Davis Institute-Jewish General Hospital (F.B., A.G., H.U.S.), Pharmacology and Therapeutics (H.U.S.), and Ophthalmology and Vision Science (H.U.S.), McGill University, Montreal, Quebec, Canada; Otonomy, Inc., San Diego, California (S.Si., S.Sz., A.C.F.); and School of Engineering Science, Simon
  • Foster AC; Lady Davis Institute-Jewish General Hospital (F.B., A.G., H.U.S.), Pharmacology and Therapeutics (H.U.S.), and Ophthalmology and Vision Science (H.U.S.), McGill University, Montreal, Quebec, Canada; Otonomy, Inc., San Diego, California (S.Si., S.Sz., A.C.F.); and School of Engineering Science, Simon
  • Saragovi HU; Lady Davis Institute-Jewish General Hospital (F.B., A.G., H.U.S.), Pharmacology and Therapeutics (H.U.S.), and Ophthalmology and Vision Science (H.U.S.), McGill University, Montreal, Quebec, Canada; Otonomy, Inc., San Diego, California (S.Si., S.Sz., A.C.F.); and School of Engineering Science, Simon
Mol Pharmacol ; 100(5): 491-501, 2021 11.
Article em En | MEDLINE | ID: mdl-34470776

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Engenharia de Proteínas / Receptores de Fatores de Crescimento / Receptor trkA / Neuroproteção / Fatores de Crescimento Neural / Proteínas do Tecido Nervoso Tipo de estudo: Prognostic_studies Limite: Animals / Humans / Male Idioma: En Revista: Mol Pharmacol Ano de publicação: 2021 Tipo de documento: Article País de publicação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Engenharia de Proteínas / Receptores de Fatores de Crescimento / Receptor trkA / Neuroproteção / Fatores de Crescimento Neural / Proteínas do Tecido Nervoso Tipo de estudo: Prognostic_studies Limite: Animals / Humans / Male Idioma: En Revista: Mol Pharmacol Ano de publicação: 2021 Tipo de documento: Article País de publicação: Estados Unidos